204 related articles for article (PubMed ID: 31188799)
1. Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM
Adv Anat Pathol; 2019 Jul; 26(4):251-256. PubMed ID: 31188799
[TBL] [Abstract][Full Text] [Related]
2. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic subtypes and bladder cancer metastasis.
McConkey DJ; Choi W; Ochoa A; Dinney CPN
Asian J Urol; 2016 Oct; 3(4):260-267. PubMed ID: 29264194
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
7. [Molecular tumor board-urothelial cancer].
Hupe MC; Gakis G; Seiler R
Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
[TBL] [Abstract][Full Text] [Related]
8. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder.
Adam RM; DeGraff DJ
Urol Oncol; 2015 Oct; 33(10):444-50. PubMed ID: 26254697
[TBL] [Abstract][Full Text] [Related]
10. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
13. Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.
Mochizuki H; Shapiro SG; Breen M
Vet Pathol; 2016 Jul; 53(4):764-72. PubMed ID: 26574558
[TBL] [Abstract][Full Text] [Related]
14. Genetic subtypes of invasive bladder cancer.
McConkey DJ; Choi W; Dinney CP
Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
[TBL] [Abstract][Full Text] [Related]
16. Non-urothelial and urothelial variants of bladder cancer.
Yu EM; Belay S; Li W; Aragon-Ching JB
Cancer Treat Res Commun; 2022; 33():100661. PubMed ID: 36442362
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
19. Molecular Subtypes of Bladder Cancer.
McConkey DJ; Choi W
Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors in urothelial carcinoma].
Vögeli TA; Ackermann R
Urologe A; 2001 Nov; 40(6):442-6. PubMed ID: 11760346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
